Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Renalytix Ai Plc LSE:RENX London Ordinary Share GB00BYWL4Y04 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -5.00 -0.78% 640.00 620.00 650.00 635.00 635.00 635.00 59,863 16:35:03
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -0.4 -1.0 - 380

Renalytix Ai Share Discussion Threads

Showing 226 to 249 of 600 messages
Chat Pages: Latest  12  11  10  9  8  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
18/6/2020
08:21
Update re Kantaros' serologic test for COVID-19 - New York, NY (June 17, 2020) Mount Sinai Health System has submitted a request to the U.S. Food and Drug Administration (FDA) for issuance of an Emergency Use Authorization (EUA) for quantitative use of its serologic test. If authorized for quantitative use, the assay could be used to provide a numeric result for the concentration of neutralizing anti-COVID-19 antibodies in plasma. In April 2020, Mount Sinai Laboratory Center for Clinical Laboratories received FDA EUA for qualitative use of the assay, an enzyme-linked immunosorbent assay or ELISA, that has now been tested on over 40,000 patients and has been a critical component of the hospital’s convalescent plasma program for emergency therapy, and testing of healthcare workers as well as the public. In a comparison of EUA tests published by the FDA (link), the EUA-authorized qualitative test had a PPV of 100%, and an NPV of 99.6%. Since then, Mount Sinai’s internationally recognized team of virologists and pathologists, including Florian Krammer, PhD, Professor of Microbiology at the Icahn School of Medicine at Mount Sinai, Carlos Cordon-Cardo, MD, PhD, Irene Heinz Given and John LaPorte Given Professor and Chair of Pathology, Molecular and Cell-Based Medicine at Mount Sinai, and Adolfo Firpo-Betancourt, MD, Professor of Pathology, Molecular and Cell Based Medicine at Mount Sinai, have been working intensely to provide new findings and data to support what they hope will be FDA authorized quantitative use of the assay. The serological assay developed by Dr. Krammer and colleagues for the screening and identification of individuals that have seroconverted was described in a paper published in Nature Medicine on May 12, 2020. Mount Sinai is hopeful that the FDA will be reviewing this request in the next few weeks. If FDA EUA is issued, Kantaro Biosciences, a Mount Sinai diagnostics venture, will also apply for FDA EUA for a commercial kit based on the Mount Sinai assay. If Kantaro’s EUA is issued, Kantaro and Bio-Techne, a leading life science tools and clinical diagnostics company, expect to provide interested laboratories access to these kits in July. Full release - hTTps://www.mountsinai.org/about/newsroom/2020/mount-sinai-seeks-eua-from-food-and-drug-administration-for-potential-quantitative-serologic-test-for-covid19-pr
wan
17/6/2020
12:54
Full quote below, there was always a lot to do...but no indication they aren’t on track "We are extremely excited to partner with Kantaro and Mount Sinai to launch what we believe will be a gold standard serology test for COVID-19," said Chuck Kummeth, President and Chief Executive Officer of Bio-Techne. "The Bio-Techne, Mount Sinai and Kantaro teams are working around the clock to develop this test, and we are on track to achieve in approximately eight weeks what would typically take 18 months or more. As the world leader in ELISA assays, Bio-Techne has substantial capacity and the ability to scale production levels to support much of our nation's needs. We look forward to providing the world with critical information related to past exposure to the virus." httpS://www.nasdaq.com/press-release/bio-techne-and-kantaro-biosciences-announce-partnership-to-develop-and-scale
74tom
17/6/2020
11:59
74tom...Thanks. To be clear, Mount Sinai was issued an Emergency Use Authorization (EUA) from the FDA for clinical testing in its CLIA certified laboratory on April 15th. Kantaro plans to seek EUA for the test kit, based on the Mount Sinai test and following final validation based on the scaled up version. Kantaro were leading regulatory processes with the intention of submitting the scaled assay for FDA EUA review in May. So, we still need obtain FDA EUA and there was quite a lot to achieve, in terms of final development and scale-up, to stay on the indicated schedule.
wan
17/6/2020
11:31
To add to the above; - It's already received FDA EUA approval and has been used in more than 30,000 tests - RENX CEO James McCullough's former company Exosome Diagnostics were acquired by Bio-techne in mid 2018, so there is a personal connection at play here by the looks of things. - The potential for global reach is real, but access to the US market is pretty much guaranteed, and that is something most companies would love to have You have to wonder what else will emerge from the RENX, Mount Sinai & Joslin Diabetes Centre partnerships in the future...
74tom
17/6/2020
11:03
I believe there are suite of important aspects that appear to set the Kantaro COVID-19 serology test apart. ELISA The ‘gold standard’ laboratory technique for serological testing, is called ELISA. The Kantaro test kit, is an enzyme-linked immunosorbent assay (ELISA) based on the Mount Sinai-developed COVID-19 serology test. As the world leader in ELISA assays, Kantaro's partner, Bio-Techne, has all the necessary credentials - Bio-Techne is a fully integrated, world leading ELISA developer and manufacturer. Accuracy - Mount Sinai Hospital Clinical Laboratory COVID-19 ELISA Antibody Test" was reported to show a Positive Predictive Value (the probability of disease if the test is positive) of 100% and a Negative Predictive Value (the probability of no disease if the test is negative) of 99.6%. Bio-Techne and Kantaro are in the process of validating the scaled assay and expect the data to confirm similar results. Availability As the world leader in ELISA assays, Bio-Techne has substantial capacity and the ability to scale production on a global scale. Ease of use A test that any medical professional can perform, hopefully, with the equipment they already own or can purchase easily, without long-term contracts and other encumbrances. In this regard, the Kantaro test kit will use a simple patient blood draw and is designed to be easily run by any laboratory in the world without costly proprietary equipment. The technology underlying the diagnostic test was created by internationally recognized virology and pathology teams from the Icahn School of Medicine at Mount Sinai.
wan
17/6/2020
09:06
Nice work as always. Yes I've been keeping an eye on the Kantoro site, I noticed last week that the availability line was changed from 'will be available soon' to 'planned for July 2020', so all appears on track...
74tom
17/6/2020
08:35
Seeing as we are fast approaching the planned availability of commercial COVID-19 test kits for clinical laboratories, which is scheduled for July 2020. I have updated the header regarding the Mount Sinai and Renalytix AI, Inc joint venture, Kantaro Biosciences. And also included a link to Kantaro's website, which is worth visiting - hTTps://kantarobio.com/
wan
16/6/2020
19:26
It’s nice to see some decent volume
nimbo1
16/6/2020
16:48
Didn't quite make it all the way back - closing bid / ask was 5.09 - 5.15 Strong after yesterday's jump, and pretty decent volume versus average totalling about £700k. Onwards and upwards!
74tom
16/6/2020
10:57
you could be right - bought a few more but they'd rather take sells than buys here
nimbo1
16/6/2020
10:50
Any consolidating will be offset by new buyers in my opinion - particularly in the US. My betting is the drop we’ve seen this morning reverses from 2pm onwards - currently I think the market markers are collecting shares to fill big delayed buys from yesterday afternoon. Nothing larger than 2.5k was declared post 4pm yet the price rose over 10% Anyway, all water under the bridge. Agree on the 3-5 year hold - just look at the growth of CareDX over the last 2 years...
74tom
16/6/2020
10:06
yes it all seems very promising. I have a 3.8 average and plan to hold for 3-5 years assuming everything goes as planned. Balancing that though we are waiting for first revenues etc and of course price will need to consolidate a bit!
nimbo1
16/6/2020
08:19
Agree Nimbo, timing the Nasdaq IPO with their first revenues was clearly the plan, and that will whet the appetite of many US investors I’d imagine, especially those aware of the macro factors. They’ve created a perfect storm as far as share price appreciation is concerned; - Existing holders have the FractalDX dividend in specie to look forward to, why would you sell when you’ll get a substantial number of free shares? - Nasdaq IPO - another exciting near term event, as we have seen with GAN this can result in a large value uplift in cases where a quality company has been relatively under the radar due to AIM liquidity. - Covid-19 involvement via Kantaro JV, this also has significant potential given the Antibody test has already received FDA EUA & has the second most accurate sensitivity / specificity of any test I’ve seen. What’s more the worldwide distribution via Bio-Techne is nailed down, so a July launch is very much on track. Expect to hear confirmation of this in the next week. Then we have the seamless underlying progress of KidneyIntelX™ described so well by Wan. Quite simply, if you sold here where else can you replicate this unique set of circumstances?
74tom
15/6/2020
22:17
My own expectations (potential £2bil + market cap in 3 years). After the recent move its a £300 mil market cap. I think over the next few months we'll see the true extent of potential - if this really is a huge improvement vs previous healthcare pathways for kidney disease I'd expect this company to be worth $1 bil+ soon after listing on nasdaq, perhaps in 6 months time. They'll be more deals with healthcare providers and insurers etc. Not to mention fda approval and eventually full Medicare coverage.
nimbo1
15/6/2020
16:50
Wan thanks. And, to put the stats another way, the US is one unhealthy country.
faz
15/6/2020
16:41
Thanks for the new thread Wan.
longshanks
15/6/2020
16:32
Thanks 74tom, I used AJ Bell instead. Nice move today.
spittingbarrel
15/6/2020
16:22
Yep, it's all to do with a restriction on US citizens buying shares which was in fact lifted on 5th May : httpS://uk.advfn.com/stock-market/london/renalytix-ai-RENX/share-news/Renalytix-AI-PLC-Removal-of-US-Securities-Law-Rest/82378186 Barclays had a block on buying it until a couple of week ago, no such issues with HL. Try a different broker if you can, as clearly II haven't been bothered to lift the restriction yet...
74tom
15/6/2020
16:15
I already hold some of these with iDealing and A.J.Bell, and just tried to buy some with Interactive Brokers, but I got the message "Transactions in this instrument are limited to closing only trades". Anyone know why that would be?
spittingbarrel
15/6/2020
12:04
Wan - thank you.
2theduke
15/6/2020
09:51
I have created a new Renalytix thread (the Stigologist beat me to it originally). The new thread better reflects that things have moved significantly beyond the admission onto AIM. So I hope that everyone will approve - Renalytix - AI Solutions Transforming The Management Of Kidney Disease hTTps://uk.advfn.com/cmn/fbb/thread.php3?id=46396409
wan
15/6/2020
09:50
I don't want readers to get ahead of themselves, especially with regard assuming the full medicare price and the full utilisation of the testing capacity, but there appears to be an assumption that the target market is limited in the US to 12 million Americans with Diabetic Kidney Disease. However, there are circa 40m people in the US with chronic kidney disease (CKD) – 12 million of these people will have Type 2 diabetes and their CKD has occurred as a result of the diabetes. So, in my opinion, it's also worth considering the significant efforts underway in the US (and elsewhere) to revolutionise identifying kidney disease early among high-risk patient populations and to better manage and thus reduce the national rate of kidney failure. e.g. In the United States, 30 million individuals have diabetes, 84 million adults have prediabetes (are at high risk for type 2 diabetes), and 75 million adults have high blood pressure. Put another way, Renalytix solutions could be used for much wider testing beyond those 'already diagnosed' with CKD to find those who have yet to be diagnosed with CKD. Earlier intervention and diagnoses would reduce complications and enable better management which would further reduce the national rate of kidney failure and increase the savings to the estimated $114 billion annual cost of chronic and end-stage kidney disease to the United States healthcare system. Clearly the market is (unfortunately) very large in the US, which I believe will be the proving ground for Renalytix as the market potential beyond the US is also very large indeed. For example in Europe, approximately 59 million people currently live with diabetes, which is set to rise to 67 million by 2045. If left untreated, patients are at greater risk of developing serious health complications, such as renal disease and cardiovascular disease, which are the two most common causes of death for Type 2 Diabetes patients. It is estimated that more than 40% of people with type 2 diabetes will develop CKD, and nearly a third will develop CVD. In any regard, if you do the maths based on the 40 million with CKD in the US, even a relatively small percentage of market penetration and a price per test ranging from $750 - $950 (my indicative range) equates to several billions in revenue. And as the data and evidence builds and the reduction in cost to the US healthcare system begins to be realised, it should make Renalytix solutions a compelling choice!
wan
13/6/2020
13:35
Many thanks for that post Wan, I’d been looking for a Nasdaq benchmark but hasn’t spotted CareDX. That is a very impressive raise, and as you say bodes very well indeed for the VericiDX spin off. My thoughts are that they’ll look to IPO around the same market cap as RENX did, so £60-70m. Where is goes from there will be very interesting indeed...
74tom
13/6/2020
12:02
Edit...CareDX link added to above post.
wan
Chat Pages: Latest  12  11  10  9  8  7  6  5  4  3  2  1
ADVFN Advertorial
Your Recent History
LSE
RENX
Renalytix ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200808 12:32:15